Company: BLLN
Filing Date: 2025-12-10
Form Type: 10-Q
Source: 0001628280-25-056321
Chunk: 386

Company: BillionToOne, Inc.
Filing Date: 2025-12-10
Form: 10-Q
Item: Part I, Item 8
Chunk 386
---
658 153.4 Operating expenses:Research and development35,134 25,600 9,534 37.2 Selling, general and administrative99,029 65,050 33,979 52.2 Total operating expenses134,163 90,650 43,513 48.0 Income (loss) from operations5,691 (35,454)41,145 116.1 Other income (expense):Interest income4,492 4,148 344 8.3 Interest expense(92)(2,339)2,247 (96.1)Net (loss) gain on extinguishment of debt- 7,289 (7,289)(100.0)Change in fair value of term loan(7,038)(2,283)(4,755)208.3 Change in fair value of convertible notes- (835)835 (100.0)Other expense, net(1,591)(614)(977)159.1 Total other (expense) income(4,229)5,366 (9,595)(178.8)Income (loss) before provision for income taxes1,462 (30,088)31,550 104.9 Provision for income taxes(15)5 (20)(400.0)Net income (loss) and comprehensive income (loss)$1,477 $(30,093)$31,570 104.9 %

Revenues

Revenue increased $101.6 million, or 95%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. This increase was driven primarily by a 52% increase in the total volume of delivered and billable tests to approximately 440,500 for the nine months ended September 30, 2025  from approximately 289,900 for the nine months ended September 30, 2024. The increase in revenue was also attributable to an increase in our Overall ASP of 30%.

We derive our revenue primarily from the number of tests processed and results delivered to the ordering physician. All tests processed are accessioned in our laboratories.

The increase in test volume was driven by higher volumes of our prenatal tests primarily as a result of expansion of our sales force for our prenatal products. In addition, volumes for both our Northstar Select and Northstar Response oncology tests increased as a result of expansion of